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Introduction
Breast cancer is the most common cancer among
women in Europe, in the United States and Australia.
It accounts for 22% of all female cancers [1]. Invasive
ductal carcinoma, not otherwise specified (ductal
NOS) s. infiltrating ductal carcinoma comprises the
largest group of invasive breast cancers [2]. The
histopathological examination of the breast cancer
bases on the morphological features but more specific
prognostic information about its biology are obtained
from the immunohistochemical (ihc) testing of the
FOLIA HISTOCHEMICA
ET CYTOBIOLOGICA
Vol. 48, No. 1, 2010
pp.19-25
Study on breast carcinoma Her2/neu and hormonal
receptors status assessed by automated images analysis
systems: ACIS III (Dako) and ScanScope (Aperio)
Janina S³odkowska1, Violetta Filas2, El¿bieta Buszkiewicz2, Pawe³ Trzeciak2,
Micha³ Wojciechowski3, Robert Koktysz1, Wojciech Staniszewski3,
Jan Brêborowicz2, Marcial Garcia Rojo4
1Department of Pathology, Military Institute of Medicine, Warsaw, 
2Department of Tumour Pathology, Wielkopolskie Center of Oncology, Poznan, 
3Precoptic, Nikon's Distributor, Warsaw, Poland,
4Pathology Department, Hospital General de Ciudad Real, Ciudad Real, Spain. 
Abstract: Her-2/neu is overexpressed in 20-30% of breast cancer patients and is associated with a more aggressive disease.
Identification of Her-2/c-erbB-2-neu overexpression is based on immunohistochemical [ihc] detection of protein and/or
gene amplification in fluorescence in situ hybridization test (FISH). Also Estrogen receptors [ER] and Progesterone recep-
tors [PR] are the prognostic and predictive biomarkers, recently analysed by ihc methods. Subjective, manual scoring of the
ihc Her-2/neu expression and expression of the ER/PR reported as the percentage of immunopositive cells are the most com-
mon mode of interpretation among pathologists. Automated microscopy and computerised processing have provided
increased accuracy in quantification and standardisation. The aims of our study were: to evaluate the scoring reproducibil-
ity of Her-2 /neu ihc expression tested by two automated systems: ACIS (Dako) and ScanScope (Aperio); to estimate the
ER/PR expression in ihc staining methods with different anti-ER/anti-PR antibodies (the monoclonal and the ER/PR phar-
mDx TM Kit ) by the ACIS system. Her-2/neu ihc expression was measured in 114 primary invasive breast carcinomas by
the manual and the automated scoring (ACIS and Aperio system). 106 slides stained ihc with two types of anti-ER/anti-PR
antibodies entered the quantisation. The results of our investigations showed very high reproducibility of Her-2/neu scores
in intra- and interobserver analysis by ACIS evaluation. The major concordance was present in strong 3+ ihc cases; very
small discordance was shown by cases with low expression of Her-2/neu. The accuracy of scoring by the Aperio was little
lower in comparison to ACIS but it might result from the smaller and variable series of samples analysed by Aperio. The
concordance in scoring of two automated systems was 86.5% (p<0.0001; γ=0.887); the discordance was referred only to the
lower expression of Her-2/neu. The concordance in manual scoring performed by the single observer and the panel was
84.2% (p<0.0001, γ = 0.99); the discordance comprised a few cases with strong expression (2+ vs 3+). Very high intra- and
interobserver reproducibility of the ER/PR ihc measurements was present in the readers results (referred to the percentage
of immunoreactive carcinomatous cell population in the breast carcinomas acc. to the ACIS algorithm). No differences were
disclosed in the percentage of ER-immunoreactive and PR-immunoreactive carcinomatous cell populations when used 2 dif-
ferent type of antibodies, in the ACIS automated method. 
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human epidermal growth factor receptor Her-2
(Her2/c-erbB-2-neu), Estrogen Receptors (ER) and
Progesterone Receptors (PR). Identification of Her-
2/c-erbB-2-neu overexpression is based on ihc detec-
tion of protein and/or gene amplification in fluores-
cence in situ hybridization test (FISH). 
Her-2/neu is overexpressed in 20-30% of breast
cancer patients; is associated with a more aggressive
disease, a poor clinical prognosis and with the targeted
therapy agent trastuzumab (Herceptin). Expression of
the ER/PR is the most reliable factor for predicting
responsiveness to hormonal therapy. The hormone
receptor expression measured ihc is accepted as stan-
dard evaluation method all over the world, but the cut
off point in ihc evaluation is still controversial.
Another controversy in testing ER /PR is a mode of
presentation of the receptors quantitation as: positive
vs negative results or the quantitative results, or both
modes. Various scoring systems have been used in ihc
evaluation of the ER/PR [3-5]. 
Several factors might be responsible for the Her-
2/neu and ER/PR ihc scoring results: the quality
assessment system, heterogeneous distribution of pos-
itive cells and staining intensity, lack of uniformity in
the manual testing, the mode of quantitation – subjec-
tive manual vs automated computerised reading, and
insufficient training of the observers. 
Automated microscopy and computerised process-
ing have provided increased accuracy in quantification
and standardisation. Use of automation in ihc interpre-
tation has decreased the number of ambiguous cases
and helped reducing the need for further testing by
another modality [6,7]. The development of the digital
pathology and telepathology has increased the interest
in implementation of the automated computerised
methods in the routine diagnostics [8,9]. 
The aims of our study were: *to evaluate the scor-
ing reproducibility of Her-2 /neu ihc expression tested
by two automated systems: ACIS (Dako) and ScanS-
cope (Aperio) used as the aids for the pathological
diagnostics of breast carcinoma; *to estimate the ER
and PR ihc expression resulted from two different ihc
staining methods: a/with the monoclonal antibodies
anti-ER and anti-PR and b/with the ER/PR pharmDx
TMKit -DAKO, by automated measurement with ACIS
system. 
Materials and methods
Her-2/neu: 114 primary invasive breast carcinomas (core biopsies
and mammotomes material) were selected for the study, from the
routine diagnostic and consultative material of the Tumour Pathol-
ogy Department, at the Wielkopolskie Center of Oncology [WCO]
(in Poznan, Poland) (from the period 2006-2008y). Tissue samples
were fixed in 10% neutral buffered formalin and processed to
paraffin blocks using standard histopathological techniques; 4 μm
paraffin sections were stained routinely with H&E. For demonstra-
tion of the Her-2 protein expression a commercially available kit
HercepTestTM (cat. no. K5204, Dako, Denmark) was used. The
deparaffinised tissue sections were rehydrated and incubated in 10
mmol/L citrate buffer (Epitope Retrieval Solution) in a water bath
95-99°C (for 40'). Next, endogenous peroxidase activity was
blocked using 3% hydrogen peroxide solution (for 5'). Subse-
quently the sections were incubated with the primary antibody, rab-
bit anti-human Her-2 (for 30', at room temperature) and incubated
with the kit Visualization Reagent (for 30' at room temperature).
The reaction product was visualized by the chromogen DAB (DAB
Substrate-Chromogen Solution). Cell nuclei were counterstained
using haematoxylin. Positive controls slides were supplied with the
HercepTest kit 9 [10].
The original glass slides of breast carcinoma were examined by
single pathologist and by the panel of pathologists of WCO, with
the light microscopes Olympus BX50 (Japan). The slides marked
for Her-2/neu membrane staining were evaluated by four-point
scoring scale: 0, 1+, 2+ and 3+ with cut off level >10%
immunopositive tumour cells [11]. For 20 out of 29 breast cancer
cases scored manually as 2+ Her2/neu, the test FISH was per-
formed. 
The automated quantisation of Her-2/neu ihc expression was
done by pairs of pathologists with ACIS (Automated Cellular
Imaging System III) (Dako, Denmark), and Aperio system (Aperio
Technologies, U.S.A.) [6,12,13]. 
ACIS: The digital images of 114 glass slides were captured
automatically by ACIS scanner at low power magnification and the
whole slide images [WSI] were viewed on a monitor. The regions
of the highest immune intensity and highest percentage of positive
cells were selected by user (or chosen from the displayed "hot
spots" formerly identified by ACIS system) for the further auto-
mated scoring. The minimum six "40x areas" (a circular field
marked automatically by the system) containing only tumour cells
were selected for a quantitative evaluation. In the process of a
region selection only the invasive carcinoma morphology (not car-
cinoma in situ areas) were analysed. WSI were evaluated 3 times
by 2 pathologists with algorithms for membrane staining (Her-2)
according to the manufacturer's manuals. A total score of Her-
2/neu expression was calculated automatically from the percentage
of immunopositive cells and immunostaining intensity, and was
shown as a mean region score for all studied regions. The final
result of Her-2/neu expression was read by the observers from four
point scale: from 0 to 3+. A cut off level for negative ihc expres-
sion was 10% population of immunopositive carcinoma cells. 
APERIO: The scanning of 114 glass slides was done manually
with Aperio Scanscope CS under 20x. The score areas were select-
ed by the free form drawings (minimum 6 score areas of various
size) and were evaluated twice by 2 pathologists under 40x with
Aperio algorithm for membrane staining, according to the manu-
facturer's manuals. Her-2/neu ihc quantisation was done automati-
cally by the system and the results were displayed in the scale from
0 to 3+. 
Estrogen and progesteron receptors. For the ER/PR study, 106
standard quality cases of the invasive breast carcinoma were
selected from the archive of the TPD WCO in Poznan (from the
period 2006-2008y). The major part of the material covered the
cases of Her-2/neu study. The breast carcinoma tissues were fixed
and processed according to the standard procedures [14].
Two types of Dako antibodies were used for the ER/PR ihc
staining. A/ The primary monoclonal antibodies anti-ER (clone 1
D5, code M 7047) and anti- PR (clone PGR 636, code M 3569) in
two-step immunohistochemistry. Sections were deparaffinized,
rehydrated and incubated in Dako Target Retrieval Solution (Code
S 1699) in a water bath at 95-99°C (for 40'). Endogenous peroxi-
dase activity was blocked using a solution of 3% hydrogen perox-
ide (for 10'). Sections were incubated with monoclonal antibodies
(anti-ER 1:50 and anti-PR 1:100) (for 60'). Subsequently, the slides
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were incubated with Dako's En-Vision Horse Radish Peroxidase
complex (Dako, code 4001) (for 30') and with DAB chromogen
solution (Dako, code K3466) (for 5'). The cell nuclei were coun-
terstained using haematoxylin. The positive control slides were
breast cancer specimens with known positive reactions. B/ The
Dako ER/PR pharmDx TMKit (ER/PR pharmDx K1904 kit for
manual use) was applied for the second type of ihc staining. The
kit contains the necessary reagents to complete the two stages ihc
method according to the manufacturer's instruction. Positive
ER/PR pharmDx Control Slides were provided by Dako.
Only good quality ihc slides were included for the quantisation
by ACIS system. In the group A: 105 ER slides and 106 PR slides;
and in the group B: 90 ER and 93 PR slides – were scanned at low
power magnification by the ACIS. The ihc expression of the
ER/PR was measured automatically in the regions selected by
users (minimum 6 areas, minimum 1000 cells) under magnifica-
tion 40x. Results of the ER/PR were presented as the percentage of
immunopositive carcinomatous cells (the ihc intensity is not
included into the algorithm of ACIS system). Each WSI was eval-
uated 3 times (a, b, c) by 2 pathologists. 
The performance of ACIS analysis enclosed many important
steps and restrictions provided by the instructions for using the
ACIS system in Her-2/neu as well as in ER/PR evaluation. Sup-
plementary to the written instruction a practical training at the
Dako Laboratory (Copenhagen, Denmark) and consultations were
necessary for an appropriate scoring.
Statistical analysis. The results of the manual and automated
counting were analysed by the statistical methods, for each studied
receptor separately. Associations between categorical variables
were evaluated by the Chi2 test or Fischer exact test and correlation
coefficient (γ). The variance analysis (ANOVA) was performed
with the post-hoc RIR-Tukey's test (for the variables with normal
distribution). The Mann-Whitney U test or Friedmann ANOVA test
were applied for variables with lack of normality. 
Results
Her-2/neu
The results of ihc Her-2/neu evaluation are presented
according to 3 modes of quantisation: manual reading
and the automated assessment by ACIS and APERIO
system. 
The comparative analysis performed for the manu-
al scores of the single observer and the panel revealed
the statistical highly significant concordance
(p<0.0001, correlation coefficient γ = 0.99 by Pear-
son's Chi2 test) in 84,2% (96/114) cases. The panel
recognised 57 (50%) scores 0/1+, 29 (25,4%) scores
2+ and 28 (24,6%) scores 3+. The single observer
recognised 50 (43,9%) scores 0/1+, 35 (30,7%) scores
2+ and 29 (25,4%) scores 3+. Thirteen discordant
scores (eight of 2+ vs 1+, and five of 2+ vs 3+) were
verified by FISH method and/or reviewed by the
pathologists.
In ACIS evaluation of 114 WSI, very high repro-
ducibility of two readers results was noticed. The high-
ly statistical significance was present in triple scoring
of each reader (E and T): p=0.0001, correlation coeffi-
cient γ = 0,999 and γ = 0,998 (Pearson's Chi2 test),
respectively. The analysis of variance (ANOVA with
post hoc RIR Tukey's) didn't show any significant dif-
ferences in E and T triple measurements of the mean
region scores (Ea-Eb, Eb-Ec, Ea-Ec and Ta-Tb, Tb-Tc,
Ta-Tc), p<0.05. The scores discordant in two readers
evaluation and the statistical data are presented in
Table 1. 
In the comparative analysis of the mean measure-
ments obtained by two readers (E and T) the concor-
dance was in 87.7% (100 out of 114) of results. The
significant difference was revealed by the analysis of
variance (ANOVA p<0.05). The comparative statisti-
cal analysis of two readers measurements revealed
strong correlation between obtained results and indi-
cate very high interobserver reproducibility for Her-2
results. 
The data of the comparative analysis of manual
scores obtained by the single reader and the scores
obtained by automated method (ACIS) are presented
in Table 2. The concordance in the reader E results was
85.1%, 81.6% and 81.6% (p<0.05, correlation coeffi-
cient : γ =-0.474, γ =-0.462 and γ =-0.478 [Pearson's
Chi2]); in the reader T results a concordance was
78.1%, 79% and 79% (p<0.05, correlation coefficient
were γ =-0.463 and γ =-0.465).
The list of discordant cases between automated and
manual evaluation of two readers: for the reader E –
Ea: 17 scores of 1+ vs 2+ ; Eb: 15 scores of 1+ vs 2+;
1 score of 2+ vs 0/1+; 5 scores of 2+ vs 3+; Ec: 16
scores of 1+ vs 2+; 5 scores of 2+ vs 3+. And for the
reader T – Ta: 1 score of 2+ vs 1+; 17 scores of 1+ and
1 score of 0 vs. 2+; 6 scores of 2+ vs. 3+; Tb: 16 scores
of 1+ vs 2+, 6 scores of 2+ vs 3+; Tc: 18 scores of 1+
vs. 2+; 5 scores of 2+ vs. 3+.When compare the man-
ual and final ACIS scores the concordance was 72.8%
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Table 1. Her-2/neu ihc measurement by the ACIS: the results of
comparative statistical analysis and a list of scores discordant
between two readers.
(83/114) and showed very high statistical significance
(p<0.0001, γ = 0.913). 31 discordant results comprise:
7 in the class 0 vs 1+, eighteen in 1+ vs 2+ and six in
2+ vs 3+. 
In Aperio study, 90 WSI were evaluated by the
reader S and 65 by the reader W; only 40 cases fitted
in both readers scoring; 24 WSI were excluded from
the analysis due to technical problems or poor quality
of images. The interobserver concordance in the scores
was 80% (32/40): (p<0.05, γ = 0.996 [Pearson's Chi2]).
The discordant results included: 7 scores 2+ vs 1+ and
1 score 3+ vs 2+. High intraobserver reproducibility
was shown in the reader W scoring (p<0.05, γ = 0.985
[Pearson's Chi2 test]). Five (13.5%) discordant results
included 3 of the class 2+ vs 1+ and 2 of the category
2+ vs 3+.
The concordance of the automated and manual
scoring in two readers evaluation was 75.4% (49/65)
and 80% (72 /90); and was statistically significant
(p<0.05, correlation coefficient γ =-0.297 and γ =-
0.367 [Pearson's Chi2 test]). The discordant cases
included: two of 2+ vs 0/1+, twelve of 1+ vs 2+; four
of 2+ vs 3+ (in the reader S study); and ten of 1+ vs 2+,
six of 2+ vs 3+ (of the reader W). When compare the
manual and final automated scoring by Aperio the con-
cordance was shown in 70.4% (57/81) results
(p<0.0001, γ = 0.794). 24 discordant scores represent-
ed the category: 0 vs 1+ in six cases; 1+ vs 2+ in thir-
teen cases, 2+ vs 3+ in five cases. 
The comparative analysis of the final Her-2/neu ihc
scores obtained by the ACIS and the Aperio, revealed
high concordance in 86.5% (70/81) scores (p<0.0001,
γ = 0.887). The discordant cases were present in 2 cat-
egories: 0 vs 1+ nine cases and 1+ vs 2+ four cases. No
discrepancy appeared in the class 2+ vs 3+. 
Estrogen and Progesterone Receptors
All results for the ER and PR ihc measurements of the
groups A and B are presented as the mean values (+/-
std. dev.) of the percentage of ER/PR-immunopositive
carcinomatous cell population.
Estrogen Receptors – Group A [A-ER]. The results
of the reader E and T (a, b, c) were as follows: 82.36
(+/- 27.68); 81,70 (+/-28.34); 81.73 (+/-28.26); and
83,47 (+/-28.44); 83.87 (+/-28.11); 84,18 (+/-27.99),
respectively; and showed very high intraobserver
reproducibility. No significant differences were pres-
ent between Ea, Eb and Ec readings (Friedman's
ANOVA N=105, df=2, p=0.45; Kendall's concordance
coefficient =0.034) nor between Ta, Tb and Tc meas-
urements (N=105, df=2, p=0.49; Kendall's concor-
dance coefficient =0.035). There were the significant
differences between measured values (p<0.01) when
compared two readers results (Ea, Eb, Ec and Ta, Tb,
Tc). 
Estrogen Receptors – Group B [B-ER]. The results
of the observer E and T presented very similar values:
77.07 (+/- 28.21), 76.93 (+/- 28.32), 76,66 (+/- 28.21)
and 79.39 (+/- 29.22), 79.27 (+/- 29.09), 79.18 (+/-
29.34), respectively. No significant differences were
noticed between Ea, Eb and Ec measurements (Fried-
man's ANOVA N=93, df=2, p=0.95; Kendall's concor-
dance coefficient =0.0006) nor between Ta, Tb and Tc
measurements (N=93, df=2, p=0.66; Kendall's concor-
dance coefficient =0.0045). The data confirm very
high intraobserver reproducibility of both readers
results. The statistically significant differences
p<0.001were shown when compared both readers
measurements (Ea, Eb, Ec and Ta, Tb, Tc).
Progesterone Receptors – Group A [A-PR]. The
measurements of the reader E and T were: 63.84 (+/-
37.27); 63.60 (+/-37.31); 63.92 (+/-37.39) and 65.98
(+/-38.27); 66.95 (+/-38.06); 66.34 (+/- 38.09), respec-
tively; and showed very high intraobserver as well
interobserver reproducibility in the statistical analysis.
No significant differences were present between Ea,
Eb and Ec measurements (Friedman's ANOVA N=106,
df=2, p=0.19; Kendall's concordance coefficient
=0.016) nor between Ta, Tb and Tc measurements
(N=106, df =2, p=0.55; Kendall's concordance coeffi-
cient =0.005). The comparison of both readers results
(Ea, Eb, Ec and Ta, Tb, Tc) showed the significant dif-
ferences between measured values (p <<0.001). 
Progesterone Receptors – Group B [B-PR]. The
results of the reader E and T showed the following val-
ues: 72.65 (+/- 32.81); 72.49 (+/-32.85) and 72.28 (+/-
32.91 and 75.02 (+/-33.51), 75.11 (+/-33.69) and 75.40
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Table 2. Her-2 scoring: discordant results between manual scoring of the single observer and reading by ACIS.
(+/-33.20), respectively. No significant differences
were present between Ea, Eb and Ec measurements
(Friedman's ANOVA N=90, df=2, p=0.81; Kendall's
concordance coefficient =0.002) nor between Ta, Tb
and Tc results (N=90, df=2, p=0.34; Kendall's concor-
dance coefficient =0.012). The statistical data con-
firmed very high intraobserver reproducibility of E
and T results. The comparison of both readers results
(Ea, Eb, Ec and Ta, Tb, Tc) indicated the statistically
significant differences p<0.001.
Estrogen Receptors in the Group A and B [A-
B/ER]. The comparative statistical analysis of ER ihc
results for the group A and B, did not reveal any sig-
nificant difference between the results in both readers
evaluation. The "p" values were as follows: p=0.404
(for Ea), p=0.498 (for Eb), p=0.445 (for Ec); p=0.548
(for Ta), p=0.479 (for Tb), p=0.419 (for Tc).
Progesteron Receptors in the Group A and B [A-
B/PR]. The analysis of variance (ANOVA) for the A-
PR and B-PR results of both readers E and T, didn't
show any significant difference between results of
both ihc staining methods (A and B). The "p" values
for the individual reading were as follows: p=0.196
(for Ea), p=0.198 (for Eb), p=0.231 (for Ec); p=0.178
(for Ta), p=0.266 (for Tb), p=0.191 (for Tc).
Discussion
Semiquantitative ihc technique is of the great impor-
tance in the routine breast cancer Her-2/neu and
ER/PR evaluation and is dependent on the observers
and the applied antibody. The tissue handling, staining
procedures and observer estimation can strongly affect
the results and cause the inter- and intraobserver diver-
sity [4,15]. For Her-2/neu study we used the validated
Dako Hercep Test ihc assay according to the guide-
lines recommended by the American Society of Clini-
cal Oncology and the College of American Patholo-
gists [4]. 
Various automated image analysis systems offer a
possibility of rapid and objective scoring of ihc stain-
ing. Her-2 is currently assessed manually by the
pathologists with various cut off thresholds (1-30%
positive tumour cells) which can lead to significant
intra- and interobserver variability. In our study a fully
automated membrane algorithm (FDA approved) has
been used for Her-2/neu assessment in ACIS III and
Aperio system with cut off threshold of 10% positive
tumour cells [6]. Both computerised image analysis
systems had installed the nuclear algorithms for the
ER/PR evaluation. 
The quantification by ACIS of Her-2/neu ihc
expression in 114 primary breast tumours, showed
very high intraobserver reproducibility of the mean
region scores (p=0.0001, γ =0.988 and γ =0.944; the
statistically significant differences: p>0.05
[ANOVA]); as well as very high interobserver repro-
ducibility of these results (concordance in 87.7%;
p<0.05 [ANOVA]). 
The concordance between automated and manual
scoring of each observer was 79% and 81.6%
(p<0.05); the concordance between the final ACIS
scoring and manual results was 86.5% (p<0.0001,γ
=0.887). 
The quantification by Aperio of Her-2/neu ihc
expression was performed in the smaller series of
breast carcinomas than in ACIS series but the data also
showed high and statistically significant intraobserver
concordance (86.5%; p<0.05, γ =0.985). The interob-
server concordance in Aperio's scores was 80% and
showed high statistical significance (p<0.05, γ
=0.996). The comparative analysis of the manual and
automated scoring by Aperio revealed statistically sig-
nificant concordance in both reader results: 75.4% and
80% (p<0.05, γ =-0.297 and γ =-0.367). The statisti-
cally significant concordance in 70.4% results
(p<0.0001, γ =0.794) appeared when compare the final
Aperio scores with the manual data. Very high concor-
dance 86.5% (p<0.0001, γ = 0.887) – was shown
between automated scoring when compare the final
scores of the ACIS and the Aperio system. These
results confirm very high accuracy of the automated
assessment by ACIS and Aperio of Her-2/neu ihc
expression.
The statistical data also indicate the higher accu-
racy the ACIS system than the Aperio in Her-2/neu
ihc assessment. However in the final interpretation of
the obtained data, should be considered several fac-
tors which could contribute in the scoring results. The
quantified series of breast carcinoma were not equal
in the ACIS and the Aperio investigations (smaller
and variable series were included to the Aperio analy-
sis). Also there was a methodological difference in
selection of counting fields: six "40x areas" by ACIS
and the free form drawings by Aperio. The third
important factor which might influence the results of
scoring was the breast carcinoma architecture and
samples quality, seen in several cases. In a few biop-
sies a structure of the intraductal carcinoma dominat-
ed over the scanty morphology of the invasive carci-
noma, makes difficult the morphological differentia-
tion and proper selection of the representative areas.
The second type of the morphological difficulties
was related to the microfocal invasion of the carcino-
matous cells, enabling a clear separation of the
minute carcinomatous foci from a stroma – especial-
ly for the automated "six 40x" method, and to some
extends for the Aperio method. Less important prob-
lem influencing the scoring results seems to be not
excellent quality of WSI due to procedure of ihc
staining. Uneven thickness of slide and/or staining
artefacts caused problem in focusing during scanning
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which was easy to overcome by the manual focusing
in the Aperio system. 
In respect to a validation of the automated scoring
results by comparison with the manual reading data,
this issue needs more extended and more precious
study. In our analysis the concordance between both
reading methods (manual and automated) was 72.8%
and 70.4% for the ACIS and the Aperio, respectively.
The concordance in the manual results of the single
observer and the panel scores was 84.2% (p<0.0001, γ
= 0.99) with 5 discordant scores within the category of
2+ vs 3+. When consider the accuracy of ACIS meas-
urements the interobserver concordance was 87.7%
without any discordant case within the category 2+ vs
3+. These results are in favour of very high accuracy
of measurements by the automated ACIS system.
Wang's et al. in the comparative study on Her-2/neu
ihc expression assessed by manual assay and with
ACIS quantitation method showed an improvement of
ACIS method over the manual method for objective
evaluation of Her-2/neu status for 2+ cases [7]. The
interobserver concordance in Aperio measurements
was 80% (but in much smaller series than ACIS popu-
lation) with one discordant case in the category 2+ vs
3+. It is impossible to exclude the contribution of the
subjectivity and the laboratory standard in the obtained
scoring results of all methods. 
Among limits of any immunohistochemical study
the most important are the specificity and sensitivity of
the antibody being used as well as the objective and
reproducible quantification. Many approaches to the
quantification of the ER/PR described in the literature
have used various antibodies [16-19]. In the current
comparative study on the ER /PR ihc expression, two
types of antibodies and adequate various staining pro-
cedures were applied: the monoclonal antibodies anti-
ER/anti-PR and the ER/PR pharmDx TMKit – both
products of Dako.
The automated algorithms that precisely quantitate
the percentage of staining and measure the intensity on
a continuous scale are better suited to provide objec-
tive data than traditional subjective methods. A num-
ber of groups have published data on the automated
assessment of the ER/PR in breast cancer [16,20-22]
describing an excellent correlation between manual
and automated analysis. Our study focused on the
quantitative analysis of the ER/PR ihc expression
when two different types of antibodies against ER and
against PR were used for the breast carcinoma sam-
ples. The quantitative measurement was performed by
the automated system ACIS. The measurements of the
percentage of the ER-immunoreactive cell population
in the breast carcinoma showed very high intraobserv-
er reproducibility for each type of anti-ER antibody (A
and B) in two readers evaluation. The statistically sig-
nificant concordance was present in the measurements
of each observer in the group A stained with the pri-
mary monoclonal antibody (p=0.027, Kendall's concor-
dance coefficient =0.034 and p=0.025; Kendall's con-
cordance coefficient =0.035 by Friedman's ANOVA)
and in the group B stained with ER pharmDxTM anti-
body (p=0.95; Kendall's concordance coefficient
=0.0005 and p=0.66; Kendall's concordance coefficient
=0.0045). Very high interobserver reproducibility of the
ER-A and ER-B results was confirmed by the statistical
comparative analysis. No significant differences were
shown between the percentage of ER-immunoreactive
populations stained by both antibodies ("p" values
ranged between p=0.404 and p=0.548). 
The measurements of the percentage of the PR-
immunoreactive carcinomatous cell population of each
type of anti-PR antibody showed very high concor-
dance in two observers evaluation. The intraobserver
concordance of each reader data for the monoclonal
anti-PR antibody results was statistically significant
(p=0.19, Kendall's concordance coefficient =0.016 and
p=0.55, Kendall's concordance coefficient =0.005 by
Friedman's ANOVA). Also the analogical measure-
ments collected for the group B (staining with the PR
pharmDxTM) showed very high intraobserver concor-
dance (p=0.81, Kendall's concordance coeffi-
cient=0.002 and p=0.34, Kendall's concordance coeffi-
cient=0.012 for each observer respectively). The sta-
tistically significant differences were present between
both readers results for the group A-PR and the group
B-PR (p<<0.001). 
The percentage of ER-immunopositive carcinoma-
tous cell populations in both ihc staining methods was
similar, no statistically significant differences between
measured values were shown (p <0.548). Also the per-
centage of PR-immonoreactive carcinomatous cell
populations didn't differ in both type of used anti-PR
antibodies (p<0.266). These results seems to be con-
tradictive to the general opinion about the Dako
ER/PR pharmDxTM Kit. Although various factors can
be assumed as the cause for this discrepancy, such as
the effect of activation by autoclaving, our small expe-
rience in this method of staining; one important factor
should be consider – the ihc intensity in quantitative
analysis of immunoreaction [17,18] . The ER/PR algo-
rithm used by ACIS system did not include the parame-
ter of ihc intensity therefore the presented results are
referred only to the percentage of immunopositive carci-
nomatous cell population. Indirectly our results support
the opinions about importance of ihc intensity measure-
ments in quantitative evaluation of immunoreactivity. 
In conclusion, our findings indicate the following:
1) The grading scores for Her-2/neu evaluated by the
ACIS showed very high reproducibility of the results
in intra- and interobserver analysis. The major concor-
dance is present in strong 3+ ihc cases; small discor-
dance occurs in the group with lower expression of
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Her-2/neu. 2) The accuracy of Her-2/neu ihc scoring
by the Aperio seems to be lower in comparison to the
ACIS but it might result from the smaller and variable
series analysed by Aperio. 3) The concordance in scor-
ing by two automated systems (ACIS and Aperio) was
86.5% (p<0.0001; γ =0.887); the discordance was
referred only to the lower expression of Her-2/neu. 4)
The concordance in manual scoring performed by the
single observer and the panel was 84.2% (p<0.0001, γ
=0.99), however the discordance comprised five cases
with strong expression (2+ vs 3+). 5) The scoring for
Her-2/neu measured manually by the single observer
and by the automated methods showed the concor-
dance in 72.8% (p<0.0001; γ =0.913) by the ACIS and
in 70.4% (p<0.0001; γ =0.794) by the Aperio. 6) Very
high intraobserver and interobserver reproducibility of
the ER/PR ihc measurements was present in both read-
ers results which were referred to the percentage of
immunoreactive carcinomatous cell population in the
breast carcinomas. 7) No differences were disclosed in
the percentage of ER-immunoreactive and PR-
immunoreactive carcinomatous cell populations when
used 2 different type of antibodies, by the ACIS auto-
mated method (which does not include the parameter
of ihc intensity). 8) The used automated methods show
very high quantitative accuracy especially ACIS sys-
tem however the interpretation of the results should
include the contribution of other factors. 
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